Oncolytics Biotech Inc. (ONCY) 10-Year Financial Performance & Capital Metrics

ONCY • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutOncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Show more

Revenue $0
EBITDA -$35M -41.0%
Net Income -$32M -54.2%
EPS (Diluted) -0.41
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -189.05% -148.5%
ROIC -
Debt/Equity 0.18 +1058.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 13.1% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 12.4x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-37.29%

EPS CAGR

10Y-

5Y-

3Y-

TTM-7.24%

ROCE

10Y Avg-107.2%

5Y Avg-85.58%

3Y Avg-91.06%

Latest-145.51%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	180.41K	162.23K	90.77K	95.38K	485.57K	332.65K	360.57K	301.11K	298.59K	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-180.41K	-162.23K	-90.77K	-95.38K	-485.57K	-332.65K	-360.57K	-301.11K	-298.59K	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0.1%	0.44%	-0.05%	-4.09%	0.31%	-0.08%	0.16%	0.01%	1%
Operating Expenses+	13.92M	15.29M	15.61M	16.66M	20.69M	18.65M	20.56M	20.38M	24.74M	34.98M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.14M	5.36M	6.21M	7.08M	8.84M	9M	10.26M	8.53M	11.62M	13.34M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	8.6M	9.77M	9.39M	9.42M	11.13M	9.65M	10.31M	11.85M	13.12M	21.65M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	180.41K	162.23K	0	0	9.56M	0	0	0	0	0
Operating Income+	-13.92M	-15.29M	-15.61M	-16.66M	-20.69M	-18.98M	-20.93M	-20.68M	-25.04M	-34.98M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.26%	-0.1%	-0.02%	-0.07%	-0.24%	0.08%	-0.1%	0.01%	-0.21%	-0.4%
EBITDA+	-13.74M	-15.13M	-15.51M	-16.57M	-20.21M	-18.65M	-20.56M	-20.38M	-24.74M	-34.88M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	0.26%	-0.1%	-0.03%	-0.07%	-0.22%	0.08%	-0.1%	0.01%	-0.21%	-0.41%
D&A (Non-Cash Add-back)	180.41K	162.23K	90.77K	95.38K	485.57K	332.65K	360.57K	301.11K	298.59K	102K
EBIT	-13.92M	-13.96M	-14.83M	-17.27M	-20.14M	-16.78M	-20.94M	-19.01M	-20.49M	-34.98M
Net Interest Income+	0	0	0	0	179.28K	90.36K	99K	528K	1.33M	1.2M
Interest Income	197.86K	163.9K	130.1K	173.5K	179.28K	90.36K	99K	528K	1.33M	1.2M
Interest Expense	0	0	0	0	0	-	0	0	0	0
Other Income/Expense	197.86K	163.9K	130.1K	173.5K	-12.43M	2.2M	-15.88K	1.67M	4.55M	3.4M
Pretax Income+	-13.72M	-15.13M	-15.48M	-16.49M	-33.12M	-16.78M	-20.94M	-19.01M	-20.49M	-31.58M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	3.15K	9.37K	141.5K	548.04K	0	0	39.42K	64.52K	71.87K	130K
Effective Tax Rate %	1%	1%	1.01%	1.03%	1.38%	1%	1%	1%	1%	1%
Net Income+	-13.72M	-15.14M	-15.62M	-17.04M	-45.55M	-16.78M	-20.98M	-19.08M	-20.56M	-31.71M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.26%	-0.1%	-0.03%	-0.09%	-1.67%	0.63%	-0.25%	0.09%	-0.08%	-0.54%
Net Income (Continuing)	-13.72M	-15.14M	-15.62M	-17.04M	-33.12M	-16.78M	-20.98M	-19.08M	-20.56M	-31.71M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.16	-1.20	-1.12	-1.06	-2.06	-0.48	-0.49	-0.43	-0.41	-0.41
EPS Growth %	0.42%	-0.03%	0.07%	0.05%	-0.94%	0.77%	-0.02%	0.12%	0.05%	0%
EPS (Basic)	-1.16	-1.20	-1.12	-1.06	-2.06	-0.48	-0.49	-0.43	-0.41	-0.41
Diluted Shares Outstanding	11.85M	12.62M	13.94M	16.02M	22.14M	40.34M	53.51M	58.03M	67.62M	76.48M
Basic Shares Outstanding	11.85M	12.62M	13.94M	16.02M	22.14M	40.34M	53.51M	58.03M	67.62M	76.48M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	26.92M	14.44M	17.82M	14.45M	18.93M	33.74M	44.9M	35.68M	38.17M	18.88M
Cash & Short-Term Investments	26.08M	14.12M	11.84M	13.7M	14.15M	31.22M	41.26M	32.14M	34.91M	15.94M
Cash Only	24.02M	12.03M	11.84M	13.7M	14.15M	31.22M	41.26M	11.67M	34.91M	15.94M
Short-Term Investments	2.06M	2.09M	0	0	0	0	0	20.47M	0	0
Accounts Receivable	340.06K	54.41K	4.8M	51.65K	0	0	866K	521K	15K	68K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	2.07M	89.66K	0	0	0	980K
Total Non-Current Assets+	459.82K	319.95K	333.44K	412.74K	727.48K	609.13K	976K	1.65M	647K	1.31M
Property, Plant & Equipment	459.82K	319.95K	333.44K	412.74K	727.48K	609.13K	976K	652K	647K	1.31M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	998K	0	0
Total Assets+	27.38M	14.76M	18.15M	14.87M	19.66M	34.35M	45.88M	37.33M	38.82M	20.19M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	0.59%	-0.46%	0.23%	-0.18%	0.32%	0.75%	0.34%	-0.19%	0.04%	-0.48%
Total Current Liabilities+	2.71M	4.07M	5.23M	2.81M	12.87M	2.71M	2.69M	3.94M	4.24M	6.69M
Accounts Payable	2.71M	4.07M	3.51M	1.83M	3.17M	1.81M	594K	2.25M	1.08M	1.09M
Days Payables Outstanding	5.48K	9.15K	14.1K	6.99K	2.39K	1.98K	601.29	2.73K	1.32K	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	927.4K	0	0	0	0	0	0
Other Current Liabilities	0	0	178.13K	988.72K	9.36M	655.21K	408K	79K	532K	1.62M
Current Ratio	9.94x	3.55x	3.41x	5.13x	1.47x	12.45x	16.69x	9.05x	9.01x	2.82x
Quick Ratio	9.94x	3.55x	3.41x	5.13x	1.47x	12.45x	16.69x	9.05x	9.01x	2.82x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	4.64M	5.86M	6.9M	6.88M	7.09M	6.89M	7.02M	7.52M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	166.43K	153.17K	361K	157K	290K	787K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	5.86M	6.73M	6.73M	0	0	0	0
Total Liabilities	2.71M	4.07M	9.87M	8.67M	19.77M	9.59M	9.78M	10.83M	11.26M	14.2M
Total Debt+	0	0	0	0	506.27K	402.06K	655K	373K	423K	1.06M
Net Debt	-24.02M	-12.03M	-11.84M	-13.7M	-13.64M	-30.82M	-40.61M	-11.29M	-34.49M	-14.88M
Debt / Equity	-	-	-	-	-	0.02x	0.02x	0.01x	0.02x	0.18x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	24.67M	10.69M	8.28M	6.2M	-107.89K	24.75M	36.1M	26.5M	27.56M	5.98M
Equity Growth %	0.79%	-0.57%	-0.23%	-0.25%	-1.02%	230.42%	0.46%	-0.27%	0.04%	-0.78%
Book Value per Share	2.08	0.85	0.59	0.39	-0.00	0.61	0.67	0.46	0.41	0.08
Total Shareholders' Equity	24.67M	10.69M	8.28M	6.2M	-107.89K	24.75M	36.1M	26.5M	27.56M	5.98M
Common Stock	261.32M	262.32M	271.71M	285.19M	311.08M	356.82M	391.35M	404.04M	430.91M	438.19M
Retained Earnings	-263.69M	-278.83M	-294.45M	-311.48M	-344.61M	-367.11M	-393.42M	-418.25M	-446M	-477.71M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	760.98K	554.06K	373.73K	607.5K	4.08M	4.02M	388K	662K	544K	961K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-15.03M	-12.48M	-14.89M	-11.92M	-19.91M	-22.07M	-22.43M	-23.36M	-28.45M	-26.97M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.24%	0.17%	-0.19%	0.2%	-0.67%	-0.11%	-0.02%	-0.04%	-0.22%	0.05%
Net Income	-13.72M	-15.14M	-15.62M	-17.04M	-33.12M	-22.51M	-26.3M	-24.84M	-27.75M	-31.71M
Depreciation & Amortization	180.41K	162.23K	90.77K	95.38K	485.57K	446.19K	452.06K	392K	403K	424K
Stock-Based Compensation	429.54K	406.08K	578.7K	1.42M	1.47M	2.56M	3.83M	2.38M	2.07M	2.72M
Deferred Taxes	-1.25M	-545.89K	0	-374.34K	12.96M	-2.85M	408.56K	0	0	0
Other Non-Cash Items	429.54K	406.08K	-124.79K	75.78K	94.82K	68.53K	91.73K	-1.68M	-4.93M	-1.94M
Working Capital Changes	-1.11M	2.23M	180.85K	3.9M	-1.8M	209.78K	-907.99K	391K	1.76M	3.54M
Change in Receivables	-148.31K	285.65K	-4.77M	4.77M	-2.02M	1.98M	-776.39K	345K	506K	-53K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-137.56K	-51.35K	1.98M	-107.47K	-10.9K	-29.3K	-285.95K	-20.4M	20.22M	-239K
Capital Expenditures	-108.27K	-23.53K	-105.77K	-107.47K	-10.9K	-29.3K	-285.95K	-55K	-8K	-239K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-29	-28	2.09M	0	0	0	0	-20.35K	0	0
Cash from Financing+	23.67M	956.13K	12.81M	13.3M	21.02M	39.77M	33.02M	12.21M	31.99M	6.64M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-19.36M	0	343.44K	124.95K	3.47M	1.94M	469.68K	12K	781K	65K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-15.14M	-12.5M	-15M	-12.03M	-19.92M	-22.1M	-22.72M	-23.41M	-28.46M	-27.2M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.24%	0.17%	-0.2%	0.2%	-0.66%	-0.11%	-0.03%	-0.03%	-0.22%	0.04%
FCF per Share	-1.28	-0.99	-1.08	-0.75	-0.90	-0.55	-0.42	-0.40	-0.42	-0.36
FCF Conversion (FCF/Net Income)	1.10x	0.82x	0.95x	0.70x	0.44x	1.32x	1.07x	1.22x	1.38x	0.85x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	136.16K	15.73K	5.45K	12K	35K	46K	120K	184K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-71.3%	-85.62%	-164.62%	-235.33%	-1496.6%	-136.16%	-68.96%	-60.95%	-76.06%	-189.05%
Return on Invested Capital (ROIC)	-6435.45%	-	-	-	-	-	-	-289.9%	-453.39%	-
Debt / Equity	-	-	-	-	-	0.02x	0.02x	0.01x	0.02x	0.18x
FCF Conversion	1.10x	0.82x	0.95x	0.70x	0.44x	1.32x	1.07x	1.22x	1.38x	0.85x

Frequently Asked Questions

Growth & Financials

Oncolytics Biotech Inc. (ONCY) grew revenue by 0.0% over the past year. Growth has been modest.

Oncolytics Biotech Inc. (ONCY) reported a net loss of $35.3M for fiscal year 2024.

Dividend & Returns

Oncolytics Biotech Inc. (ONCY) has a return on equity (ROE) of -189.1%. Negative ROE indicates the company is unprofitable.

Oncolytics Biotech Inc. (ONCY) had negative free cash flow of $26.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Oncolytics Biotech Inc. (ONCY) 10-Year Financial Performance & Capital Metrics

ONCY • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$35M -41.0%
Net Income -$32M -54.2%
EPS (Diluted) -0.41
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -189.05% -148.5%
ROIC -
Debt/Equity 0.18 +1058.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 13.1% in last year
✗Trading more than 30% below 52-week high
✗Expensive at 12.4x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-37.29%

EPS CAGR

10Y-

5Y-

3Y-

TTM-7.24%

ROCE

10Y Avg-107.2%

5Y Avg-85.58%

3Y Avg-91.06%

Latest-145.51%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	180.41K	162.23K	90.77K	95.38K	485.57K	332.65K	360.57K	301.11K	298.59K	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-180.41K	-162.23K	-90.77K	-95.38K	-485.57K	-332.65K	-360.57K	-301.11K	-298.59K	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	0.1%	0.44%	-0.05%	-4.09%	0.31%	-0.08%	0.16%	0.01%	1%
Operating Expenses+	13.92M	15.29M	15.61M	16.66M	20.69M	18.65M	20.56M	20.38M	24.74M	34.98M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.14M	5.36M	6.21M	7.08M	8.84M	9M	10.26M	8.53M	11.62M	13.34M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	8.6M	9.77M	9.39M	9.42M	11.13M	9.65M	10.31M	11.85M	13.12M	21.65M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	180.41K	162.23K	0	0	9.56M	0	0	0	0	0
Operating Income+	-13.92M	-15.29M	-15.61M	-16.66M	-20.69M	-18.98M	-20.93M	-20.68M	-25.04M	-34.98M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	0.26%	-0.1%	-0.02%	-0.07%	-0.24%	0.08%	-0.1%	0.01%	-0.21%	-0.4%
EBITDA+	-13.74M	-15.13M	-15.51M	-16.57M	-20.21M	-18.65M	-20.56M	-20.38M	-24.74M	-34.88M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	0.26%	-0.1%	-0.03%	-0.07%	-0.22%	0.08%	-0.1%	0.01%	-0.21%	-0.41%
D&A (Non-Cash Add-back)	180.41K	162.23K	90.77K	95.38K	485.57K	332.65K	360.57K	301.11K	298.59K	102K
EBIT	-13.92M	-13.96M	-14.83M	-17.27M	-20.14M	-16.78M	-20.94M	-19.01M	-20.49M	-34.98M
Net Interest Income+	0	0	0	0	179.28K	90.36K	99K	528K	1.33M	1.2M
Interest Income	197.86K	163.9K	130.1K	173.5K	179.28K	90.36K	99K	528K	1.33M	1.2M
Interest Expense	0	0	0	0	0	-	0	0	0	0
Other Income/Expense	197.86K	163.9K	130.1K	173.5K	-12.43M	2.2M	-15.88K	1.67M	4.55M	3.4M
Pretax Income+	-13.72M	-15.13M	-15.48M	-16.49M	-33.12M	-16.78M	-20.94M	-19.01M	-20.49M	-31.58M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	3.15K	9.37K	141.5K	548.04K	0	0	39.42K	64.52K	71.87K	130K
Effective Tax Rate %	1%	1%	1.01%	1.03%	1.38%	1%	1%	1%	1%	1%
Net Income+	-13.72M	-15.14M	-15.62M	-17.04M	-45.55M	-16.78M	-20.98M	-19.08M	-20.56M	-31.71M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.26%	-0.1%	-0.03%	-0.09%	-1.67%	0.63%	-0.25%	0.09%	-0.08%	-0.54%
Net Income (Continuing)	-13.72M	-15.14M	-15.62M	-17.04M	-33.12M	-16.78M	-20.98M	-19.08M	-20.56M	-31.71M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.16	-1.20	-1.12	-1.06	-2.06	-0.48	-0.49	-0.43	-0.41	-0.41
EPS Growth %	0.42%	-0.03%	0.07%	0.05%	-0.94%	0.77%	-0.02%	0.12%	0.05%	0%
EPS (Basic)	-1.16	-1.20	-1.12	-1.06	-2.06	-0.48	-0.49	-0.43	-0.41	-0.41
Diluted Shares Outstanding	11.85M	12.62M	13.94M	16.02M	22.14M	40.34M	53.51M	58.03M	67.62M	76.48M
Basic Shares Outstanding	11.85M	12.62M	13.94M	16.02M	22.14M	40.34M	53.51M	58.03M	67.62M	76.48M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	26.92M	14.44M	17.82M	14.45M	18.93M	33.74M	44.9M	35.68M	38.17M	18.88M
Cash & Short-Term Investments	26.08M	14.12M	11.84M	13.7M	14.15M	31.22M	41.26M	32.14M	34.91M	15.94M
Cash Only	24.02M	12.03M	11.84M	13.7M	14.15M	31.22M	41.26M	11.67M	34.91M	15.94M
Short-Term Investments	2.06M	2.09M	0	0	0	0	0	20.47M	0	0
Accounts Receivable	340.06K	54.41K	4.8M	51.65K	0	0	866K	521K	15K	68K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	2.07M	89.66K	0	0	0	980K
Total Non-Current Assets+	459.82K	319.95K	333.44K	412.74K	727.48K	609.13K	976K	1.65M	647K	1.31M
Property, Plant & Equipment	459.82K	319.95K	333.44K	412.74K	727.48K	609.13K	976K	652K	647K	1.31M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	998K	0	0
Total Assets+	27.38M	14.76M	18.15M	14.87M	19.66M	34.35M	45.88M	37.33M	38.82M	20.19M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	0.59%	-0.46%	0.23%	-0.18%	0.32%	0.75%	0.34%	-0.19%	0.04%	-0.48%
Total Current Liabilities+	2.71M	4.07M	5.23M	2.81M	12.87M	2.71M	2.69M	3.94M	4.24M	6.69M
Accounts Payable	2.71M	4.07M	3.51M	1.83M	3.17M	1.81M	594K	2.25M	1.08M	1.09M
Days Payables Outstanding	5.48K	9.15K	14.1K	6.99K	2.39K	1.98K	601.29	2.73K	1.32K	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	1000K	927.4K	0	0	0	0	0	0
Other Current Liabilities	0	0	178.13K	988.72K	9.36M	655.21K	408K	79K	532K	1.62M
Current Ratio	9.94x	3.55x	3.41x	5.13x	1.47x	12.45x	16.69x	9.05x	9.01x	2.82x
Quick Ratio	9.94x	3.55x	3.41x	5.13x	1.47x	12.45x	16.69x	9.05x	9.01x	2.82x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	4.64M	5.86M	6.9M	6.88M	7.09M	6.89M	7.02M	7.52M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	166.43K	153.17K	361K	157K	290K	787K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	5.86M	6.73M	6.73M	0	0	0	0
Total Liabilities	2.71M	4.07M	9.87M	8.67M	19.77M	9.59M	9.78M	10.83M	11.26M	14.2M
Total Debt+	0	0	0	0	506.27K	402.06K	655K	373K	423K	1.06M
Net Debt	-24.02M	-12.03M	-11.84M	-13.7M	-13.64M	-30.82M	-40.61M	-11.29M	-34.49M	-14.88M
Debt / Equity	-	-	-	-	-	0.02x	0.02x	0.01x	0.02x	0.18x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	24.67M	10.69M	8.28M	6.2M	-107.89K	24.75M	36.1M	26.5M	27.56M	5.98M
Equity Growth %	0.79%	-0.57%	-0.23%	-0.25%	-1.02%	230.42%	0.46%	-0.27%	0.04%	-0.78%
Book Value per Share	2.08	0.85	0.59	0.39	-0.00	0.61	0.67	0.46	0.41	0.08
Total Shareholders' Equity	24.67M	10.69M	8.28M	6.2M	-107.89K	24.75M	36.1M	26.5M	27.56M	5.98M
Common Stock	261.32M	262.32M	271.71M	285.19M	311.08M	356.82M	391.35M	404.04M	430.91M	438.19M
Retained Earnings	-263.69M	-278.83M	-294.45M	-311.48M	-344.61M	-367.11M	-393.42M	-418.25M	-446M	-477.71M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	760.98K	554.06K	373.73K	607.5K	4.08M	4.02M	388K	662K	544K	961K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-15.03M	-12.48M	-14.89M	-11.92M	-19.91M	-22.07M	-22.43M	-23.36M	-28.45M	-26.97M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.24%	0.17%	-0.19%	0.2%	-0.67%	-0.11%	-0.02%	-0.04%	-0.22%	0.05%
Net Income	-13.72M	-15.14M	-15.62M	-17.04M	-33.12M	-22.51M	-26.3M	-24.84M	-27.75M	-31.71M
Depreciation & Amortization	180.41K	162.23K	90.77K	95.38K	485.57K	446.19K	452.06K	392K	403K	424K
Stock-Based Compensation	429.54K	406.08K	578.7K	1.42M	1.47M	2.56M	3.83M	2.38M	2.07M	2.72M
Deferred Taxes	-1.25M	-545.89K	0	-374.34K	12.96M	-2.85M	408.56K	0	0	0
Other Non-Cash Items	429.54K	406.08K	-124.79K	75.78K	94.82K	68.53K	91.73K	-1.68M	-4.93M	-1.94M
Working Capital Changes	-1.11M	2.23M	180.85K	3.9M	-1.8M	209.78K	-907.99K	391K	1.76M	3.54M
Change in Receivables	-148.31K	285.65K	-4.77M	4.77M	-2.02M	1.98M	-776.39K	345K	506K	-53K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-137.56K	-51.35K	1.98M	-107.47K	-10.9K	-29.3K	-285.95K	-20.4M	20.22M	-239K
Capital Expenditures	-108.27K	-23.53K	-105.77K	-107.47K	-10.9K	-29.3K	-285.95K	-55K	-8K	-239K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-29	-28	2.09M	0	0	0	0	-20.35K	0	0
Cash from Financing+	23.67M	956.13K	12.81M	13.3M	21.02M	39.77M	33.02M	12.21M	31.99M	6.64M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-19.36M	0	343.44K	124.95K	3.47M	1.94M	469.68K	12K	781K	65K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-15.14M	-12.5M	-15M	-12.03M	-19.92M	-22.1M	-22.72M	-23.41M	-28.46M	-27.2M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.24%	0.17%	-0.2%	0.2%	-0.66%	-0.11%	-0.03%	-0.03%	-0.22%	0.04%
FCF per Share	-1.28	-0.99	-1.08	-0.75	-0.90	-0.55	-0.42	-0.40	-0.42	-0.36
FCF Conversion (FCF/Net Income)	1.10x	0.82x	0.95x	0.70x	0.44x	1.32x	1.07x	1.22x	1.38x	0.85x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	136.16K	15.73K	5.45K	12K	35K	46K	120K	184K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-71.3%	-85.62%	-164.62%	-235.33%	-1496.6%	-136.16%	-68.96%	-60.95%	-76.06%	-189.05%
Return on Invested Capital (ROIC)	-6435.45%	-	-	-	-	-	-	-289.9%	-453.39%	-
Debt / Equity	-	-	-	-	-	0.02x	0.02x	0.01x	0.02x	0.18x
FCF Conversion	1.10x	0.82x	0.95x	0.70x	0.44x	1.32x	1.07x	1.22x	1.38x	0.85x

Frequently Asked Questions

Growth & Financials

Oncolytics Biotech Inc. (ONCY) grew revenue by 0.0% over the past year. Growth has been modest.

Oncolytics Biotech Inc. (ONCY) reported a net loss of $35.3M for fiscal year 2024.

Dividend & Returns

Oncolytics Biotech Inc. (ONCY) has a return on equity (ROE) of -189.1%. Negative ROE indicates the company is unprofitable.

Oncolytics Biotech Inc. (ONCY) had negative free cash flow of $26.5M in fiscal year 2024, likely due to heavy capital investments.